<SEC-DOCUMENT>0001279569-20-001105.txt : 20200728
<SEC-HEADER>0001279569-20-001105.hdr.sgml : 20200728
<ACCEPTANCE-DATETIME>20200728162439
ACCESSION NUMBER:		0001279569-20-001105
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200728
FILED AS OF DATE:		20200728
DATE AS OF CHANGE:		20200728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		201054163

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16 </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of July 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410 </B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway, Vancouver,
British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Form 20-F <FONT STYLE="font-family: Wingdings">x</FONT>
Form 40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following exhibits included herein were filed by the Registrant
with the Canadian securities regulatory authorities on the System for Electronic Document Analysis and Retrieval on the dates noted
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Exhibit 99.1</FONT></TD>
    <TD STYLE="width: 82%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">News Release date July 28, 2020: ESSA Pharma Announces Proposed
        Public Offering of Common Shares</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">This report on Form 6-K shall be incorporated by reference into
the registrant&rsquo;s Registration Statements on Form F-3 (File No.&nbsp;333-222654 and File No. 333-234136) and Form S-8 (File
No. 333-225056) under the Securities Act of 1933, as amended.</P>



<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><B>EXHIBITS
INCLUDED AS PART OF THIS REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 3%">&nbsp;</TD>
    <TD STYLE="width: 89%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt; line-height: 107%"><B>Exhibit</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">Exhibit 99.1</A></FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">News
    Release date July 28, 2020: ESSA Pharma Announces Proposed Public Offering of Common Shares</A></FONT>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT>
        <FONT STYLE="font-size: 10pt">P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT> <FONT STYLE="font-size: 10pt">I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 107%">Date: July 28,
    2020</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt; line-height: 107%">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT> <FONT STYLE="font-size: 10pt">W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>





<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JULY 28, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0; text-align: left">&nbsp;<IMG SRC="essalogo.jpg" ALT="" STYLE="width: 177px; height: 76px"></P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">ESSA Pharma Announces Proposed Public
Offering of Common Shares</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">VANCOUVER,&nbsp;BC and HOUSTON, July 28, 2020
/CNW/ -<B>&nbsp;</B>ESSA Pharma Inc. (&quot;ESSA&quot;, or the &quot;Company&quot;) (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage
pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer,&nbsp;today announced that it
has commenced an underwritten public offering of its common shares (the &quot;Offering&quot;). ESSA intends to use the net proceeds
of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well
as working capital and general corporate purposes. In connection with the Offering, ESSA expects to grant the underwriters a 30-day
option to purchase up to an additional 15% of the common shares offered in the Offering (the &quot;Option&quot;). All common shares
to be sold in the Offering will be offered by ESSA. The Offering is subject to market conditions, and there can be no assurance
as to whether or when the Offering may be completed, or the actual size or terms of the Offering.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Jefferies is acting as sole book-running manager
for the Offering.&nbsp;Oppenheimer &amp; Co. is acting as lead manager for the Offering and Bloom Burton Securities Inc. is acting
as co-manager for the Offering.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The securities described above are being offered
by ESSA in the United States pursuant to a shelf registration statement on Form F-3 (File No. 333-225969) that was previously filed
by ESSA with the Securities and Exchange Commission (the &quot;SEC&quot;) and became effective on July 17, 2018 and in Canada pursuant
to ESSA's Canadian short form base shelf prospectus (the &quot;Canadian Base Shelf Prospectus&quot;) dated July 12, 2018 that was
previously filed with the securities regulatory authorities in each of the provinces of British Columbia, Alberta and Ontario.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">For any common shares issued pursuant to the
Offering on or after the expiry of the Canadian Base Shelf Prospectus, including any common shares issued upon exercise of the
Option, the Company will rely on the temporary exemptive relief granted pursuant to British Columbia Instrument 51-517 &ndash;
<I>Temporary Exemption from Certain Corporate Finance Requirements with Deadlines during the Period from June 2 to August 31, 2020</I>,
Alberta Securities Commission Blanket Order 51-519 &ndash; <I>Temporary Exemption from Certain Corporate Finance Requirements with
Deadlines during the Period from June 2 to August 31, 2020</I>, and Ontario Instrument 51-505 &ndash; <I>Temporary Exemption from
Certain Corporate Finance Requirements with Deadlines during the Period from June 2 to August 31, 2020</I> to extend the expiry
date of the Canadian Base Shelf Prospectus by 45 days.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">A preliminary prospectus supplement and accompanying
prospectus relating to the Offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov.
A preliminary prospectus supplement to ESSA's Canadian Base Shelf Prospectus will also be filed with the securities regulatory
authorities in each of the provinces of British Columbia, Alberta and Ontario and will be available at http://www.sedar.com. A
copy of the preliminary prospectus supplement and accompanying prospectus can be obtained by contacting Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by e-mail at prospectus_department@jefferies.com
or by telephone at (877) 547-6340.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The Offering is subject to customary closing
conditions, including Nasdaq and TSX Venture Exchange approvals.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">This press release does not constitute an offer
to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About ESSA Pharma Inc.</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">ESSA is a clinical-stage pharmaceutical company
focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer in patients whose
disease is progressing despite treatment with current therapies. The Company filed an IND with the U.S. Food and Drug Administration
for EPI-7386 in the first calendar quarter of 2020 and clearance was received April 30,2020. A Clinical Trial Application was filed
with Health Canada in April 2020.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B><I>Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.</I></B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Forward-Looking Statement Disclaimer</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
This release contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the meaning
of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;anticipate&quot;, &quot;believe&quot;, &quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;,
statements that an action or event &quot;may&quot;, &quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot;
be taken or occur, or other similar expressions and includes, but is not limited to, statements regarding our expectations of the
Offering, the granting of the Option, the closing of the Offering and the receipt of the approval of Nasdaq and the TSX-V, the
anticipated use of proceeds from the Offering, and other information that is not historical information.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking statements and information
are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict,
and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied
thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and
are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such
statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties
and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited
to (i) the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; (iv) general business, market and economic conditions; and (v) the satisfaction of customary closing conditions
related to the proposed Offering.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking information is developed based
on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated
December 19, 2019 under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile on the SEDAR website
at www.sedar.com, and on ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR and
EDGAR profiles. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements
are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other
circumstances should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned
against attributing undue certainty to forward-looking statements.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content:http://www.prnewswire.com/news-releases/essa-pharma-announces-proposed-public-offering-of-common-shares-301101497.html</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content: http://www.newswire.ca/en/releases/archive/July2020/28/c9258.html</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001633932</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>Company Contact: David Wood, Chief
Financial Officer, ESSA Pharma Inc., Contact: (778) 331-0962, Email: dwood@essapharma.com; Investor Relations Contact: Alan Lada,
Vice President, Solebury Trout, Contact: (617) 221-8006, Email: alada@SoleburyTrout.com</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 16:01e 28-JUL-20</P>



<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>essalogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 essalogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "! 7P# 2(  A$! Q$!_\0
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M!2I>6TCA$N(F8] K@DT[,7,NY/1112&%%%% !1110 5X9\8?^1Q@_P"O%/\
MT-Z]SKPSXP_\CC!_UXI_Z&]=N7_Q_DSS\R_@?-'G^*,45/;6=U>,RVMM-.RC
M)$498@?A7NNRU9X"N]B#%&*O_P!A:O\ ] J^_P# =_\ "C^PM7_Z!5]_X#O_
M (5//#NA\D^S*&*,5?\ ["U?_H%7W_@._P#A1_86K_\ 0*OO_ =_\*.>'=!R
M3[,H8JUI@_XFUG_UW3_T(5+_ &%J_P#T"K[_ ,!W_P *M:;HFK)JEHS:7>A1
M,A)-N^!\P]JF4X<KU1482NM&?35%%%?,GU@5%<W,%G;27%Q*D4,8W.[G 44]
MW6-"[$!0,DGH*^?O'GC.X\2ZG);V\K+I<+8B0' D(_C/K[>@_&NC#X=UI66Q
MS8K$QH1N]WL=3X@^,!#/!H-L"!Q]IN!U]U7_ !_*O/\ 4O%FO:L3]LU2Y=3_
M  *VQ/\ OE<"L:E +,%4$D] .]>W3PU*FM$>!5Q56J_>8G4T=*TXO#>N3H'B
MT;4'4]&6V<@_I45SHVJ6:EKK3;R!1U,L#*/U%:\\-KK\#+DGO9_B3V'B;6],
M(^QZK=Q*.B>:2O\ WR>/TKL=&^+^K6I6/5+>*]C[NF(W_3@_D*\YHJ)X>E4^
M*)=/$5:?PR9],>'O%>D^);;S+"XS(OWX7XD3ZC^HR*VZ^4K6[N+&YCN;69X9
MXSE)$."#7T%X \0W_B+0!<ZA;&.1&V"8#"S8ZL!V]#VST]!Y&*P?L5S1>A[6
M#QOMGR26IU=%%%<)Z 5C>(O$^F>&;+[1?S$,W$<2#+R'V']>E'BCQ!;^&]#G
MU";#,/EBCS]]ST'^/L#7SEJNJWNM:A)>W\[2S2'J>BCT [#VKLPF$=9W>QPX
MS&>P7+'XCL];^+.MW[-'IJQV$'8@!Y#]21@?@/QKB[[5=1U-R]]?7%R?^FLA
M;'TSTJG4MO:W%W)Y=M!+,_\ =C0L?R%>S"C2IKW4D>'.M5JOWFV14^*62&02
M12/&XZ,C$$5I?\(OX@"[O[#U+'_7H_\ A5&YLKJS;;=6TT!/:6,J?UJU*$M$
MT9N,EJTS;T[QWXETPCR=6GD0?P3GS1CT^;)'X5WFA_&*.1DAUNS\HG@SV_*C
MZJ>1^!/TKR&BL:F%I5-U]QO2Q=:G\,CZKL[VUU"U2YM)XYH7&5=#D&K%?-'A
MGQ-JGAS4%DT]V=78![8Y*R^V/7T(YKZ1M)7GM(I98FAD= S1L02A(Z''I7C8
MG#.@][IGN87%+$+:S1-1117,=84444 %>-_&'7?/U"VT2,_);CSI?]\CY1^
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M "'-2_Z]Q_Z$*]3&?P)'DX+_ 'B)[/BC%%%?/'TP8HQ110 8I,"EHH ****
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M?VG'^7\3T/[*G_,CY>HKZA_X1_1_^@58_P#@.G^%'_"/Z/\ ] JQ_P# =/\
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M3XM3PC?W-R]FUR)HPFU9-N.<YZ&N7HKVYPC.+C+8\*G.5.2E'='KW_"ZH/\
MH"2_^! _^)H_X75!_P! 27_P('_Q->0T5S?4:';\3J_M#$?S?@CU[_A=4'_0
M$E_\"!_\31_PNJ#_ * DO_@0/_B:\AHH^HT.WXA_:&(_F_!'KW_"ZH/^@)+_
M .! _P#B:EMOC)#<W4, T613(ZIG[0.,G']VO'*M:7_R%K+_ *[I_P"A"E+
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
